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Abstract
Background: Rapid new diagnostic methods (including Xpert MTB/RIF assay) use rifampicin resistance as a surrogate marker
for multidrug resistant tuberculosis. Patients infected with rifampicin susceptible strains are prescribed first line anti-
tuberculosis therapy. The roll out of such methods raises a concern that strains with resistance to other first line anti-
tuberculosis drugs including isoniazid will be missed and inappropriate treatment given. To evaluate implications of using
such methods review of resistance data from high burden settings such as ours is essential.
Objective: To determine resistance to first line anti-tuberculosis drugs amongst rifampicin susceptible pulmonary
Mycobacterium tuberculosis (MTB) isolates from Pakistan.
Materials and Methods: Data of pulmonary Mycobacterium tuberculosis strains isolated in Aga Khan University Hospital
(AKUH) laboratory (2009–2011) was retrospectively analyzed. Antimicrobial susceptibility profile of rifampicin susceptible
isolates was evaluated for resistance to isoniazid, pyrazinamide, ethambutol, and streptomycin.
Results: Pulmonary specimens submitted to AKUH from 2009 to 2011 yielded 7738 strains of Mycobacterium tuberculosis.
These included 54% (n 4183) rifampicin susceptible and 46% (n: 3555) rifampicin resistant strains. Analysis of rifampicin
susceptible strains showed resistance to at least one of the first line drugs in 27% (n:1133) of isolates. Overall isoniazid
resistance was 15.5% (n: 649), with an isoniazid mono-resistance rate of 4% (n: 174). Combined resistance to isoniazid,
pyrazinamide, and ethambutol was noted in 1% (n: 40), while resistance to isoniazid, pyrazinamide, ethambutol, and
streptomycin was observed in 1.7% (n: 70) of strains.
Conclusions: Our data suggests that techniques (including Xpert MTB/RIF assay) relying on rifampicin susceptibility as an
indicator for initiating first line therapy will not detect patients infected with MTB strains resistant to other first line drugs
(including isoniazid). The roll out of these techniques must therefore be accompanied by strict monitoring ensuring early
resistance detection to increase chances of improved patient outcomes.
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Introduction
Use of Xpert MTB/RIF assay has been endorsed by the World
Health Organization (WHO) as a rapid method for simultaneous
detection of MTB and rifampicin resistance (as a surrogate marker
for multidrug resistant tuberculosis [MDR-TB]). Current recom-
mendations suggest that tuberculosis (TB) patients infected with
rifampicin susceptible MTB diagnosed on the basis Xpert MTB/
RIF assay be prescribed first line anti-tuberculosis therapy (ATT)
[isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E)/
streptomycin (S)] [1]. This recommendation however raises a
concern that isolates susceptible to rifampicin but resistant to other
first line ATT especially isoniazid will not be detected by Xpert
MTB/RIF. In such cases where standard DOTS regimen
(2HREZ/4HR) is used, patients receiving rifampicin and isoniazid
during continuation phase would effectively only be on rifampicin
monotherapy and thus at risk of therapeutic failure and of
emergence of MDR-TB. These concerns are supported by recent
studies suggesting poor outcome in isoniazid mono-resistant TB
cases treated with standard first line therapy [2–4].
Globally, isoniazid resistance alone or in combination with
other drugs has an estimated prevalence of 10.3% amongst new
cases, 27.7% amongst previously treated patients and 13.3% for
combined (new and retreated) cases [5]. Isoniazid resistance
amongst new, previously treated and combined cases within
South-East Asian region is estimated at 10.3%, 36.8% and 15.7%
and in Pakistan at 8.9%, 28.5% and 18.7% respectively [5], [6].
Isoniazid monoresistance rates in different parts of the world vary
from 4–48% [7-9] and are reported as being 3%, 6.3% and 4.6%
from Pakistan in the respective case categories listed above [6].
Among rifampicin susceptible TB isolates, a retrospective
analysis of aggregated data documents isoniazid resistance rate
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(alone and in combination with other drugs) of 7.2%, 15.3% and
7.7% in new, retreated and combined cases respectively [10].
With the roll out of Xpert MTB/RIF assay for TB diagnosis, it
becomes extremely important to determine the prevalence of first
line ATT resistance in rifampicin susceptible TB cases in different
geographical locations. Thus, we aimed to study resistance rate to
isoniazid and other first line ATT in rifampicin susceptible
pulmonary MTB isolates from Pakistan.
Methods
Ethical Statement
This study and consent procedures were approved by the Ethics
Review Committee of the Aga Khan University Hospital (AKUH),
Pakistan. It is a retrospective analysis of antimicrobial resistance
amongst MTB strains isolated in the clinical laboratory for
diagnostic purposes. Specific verbal or written consent from
patients was not required as the data used was obtained from
laboratory records and used anonymously.
Study Design
This was a retrospective cross sectional study, conducted at the
AKUH clinical microbiology laboratory. The hospital and its
clinical laboratory are accredited by the Joint Commission of
International Accreditation (JCIA) and designated as a technical
partner of the National TB program (NTP). The laboratory
participates in external quality control surveys with the College of
American Pathologists (CAP). MTB susceptibility testing is further
validated by the WHO Supranational Laboratory quality assur-
ance program.
There are only a few laboratories in the country offering drug
susceptibility testing (DST) for MTB. The AKUH laboratory has a
wide DST network; it receives specimens collected through more
than 175 collection units located in major cities and towns across
the country. Specimens for TB cultures are requested by
physicians as required and are received through passive specimen
collection. All of the specimens collected at each of the collection
units are sent to the main laboratory in Karachi for TB cultures
and DST. In the absence of a national DST program the data
presented here were not collected in a programmed survey of drug
resistance but obtained as part of routine analysis of specimens
submitted to the laboratory between January 2009 and December
2011.
Data retrieved from centralized database of all clinical
pulmonary (sputum, tracheal aspirates and bronchoalveolar
lavage) samples yielding growth of MTB during study period
was included. Antimicrobial susceptibility profile of rifampicin
susceptible isolates was evaluated for isoniazid, pyrazinamide,
ethambutol and streptomycin resistance rates. Due to unavailabil-
ity of prior treatment history combined resistance rate was
assessed. Duplicate specimens from same patients were excluded.
Isolation of Mycobacterium Tuberculosis
Isolation of MTB during the study period was performed using
standard methodology. Both Lowenstein-Jensen (LJ) media and
Mycobacteria growth indicator tubes (MGIT) (Becton Dickinson)
were used for isolation of MTB from pulmonary specimens. MTB
was identified by the BACTEC NAP TB differentiation test
(Becton Dickinson, USA), growth on p-nitrophenyl butyrate (PNB)
containing media, nitrate reduction and niacin accumulation tests.
Antimicrobial Susceptibility Test
Antimicrobial susceptibility testing for all ATT except pyrazin-
amide were performed using agar proportion method on enriched
Middle brook 7 H10 medium (BBL) at the following concentra-
tions; rifampicin, 1 ug/ml; isoniazid, 0.2 ug/ml and 1 ug/ml;
streptomycin 2 ug/ml and 10 ug/ml; ethambutol 5 ug/ml and
10 ug/ml. Pyrazinamide susceptibility was carried out using the
BACTEC 7 H12 medium pH 6?0 at 100 ug/ml (BACTECTM
Pyrazinamide test medium, Becton Dickinson USA). For purpose
of this study a cut off concentration of 0.2 ug/ml for isoniazid,
5 ug/ml for ethambutol and 2 ug/ml for streptomycin was used.
MTB H37Rv was used as control with each batch of susceptibility
tests.
Data Management and Statistical Analysis
Data extracted from the computerized information system of
the hospital were transferred to the statistical software SPSS
version 19.0. Frequencies with percentages for drug resistance
were computed for each drug alone and in different combinations.
Results
A total of 7738 MTB strains isolated during the study period
(2009–2011) were included. These strains were obtained from
pulmonary specimen received from different provinces of the
country; 28% (n:2196) from Punjab, 55% (n:4250) from Sindh,
14% (n:1056) from Khyber Pakhtunkhwa (KPK) and 3% (n:233)
from Balochistan. Of the total isolates studied 54% (n:4183) were
rifampicin susceptible while 46% (n:3555) were rifampicin
resistant.
Resistance to at least one of the other first line drugs; isoniazid,
ethambutol, pyrazinamide and streptomycin was seen in 27%
(n:1133) of rifampicin susceptible isolates. Amongst these overall
isoniazid resistance was 15.5% (n:649) with an isoniazid mono-
resistance rate of 4% (n:174). Resistance to the drug combination
(isoniazid, pyrazinamide and ethambutol) used during intensive
phase of treatment was noted in 1% (n:40), while resistance to all
first line agents (isoniazid, ethambutol, pyrazinamide and strep-
tomycin) noted in 1.7% (n:70) of rifampicin susceptible isolates
(Table 1).
Province wise analysis of rifampicin susceptible/isoniazid
monoresistant isolates (Table 2) suggests that these strains are
distributed across the country and not part of a localized clonal
outbreak or representative of patients from any specific niche.
Similar geographical spread was seen for strains that were
rifampicin susceptible/resistant to other first line drugs.
Discussion
Rapid new diagnostic methods (including Xpert MTB/RIF
assay) use rifampicin resistance as a surrogate marker for MDR-
TB. Patients infected with rifampicin susceptible strains are
prescribed first line ATT [1]. Our study suggests that in 27% of
TB cases in this population, use of rifampicin susceptibility alone
as an indication for first line ATT will fail to take into
consideration resistance to at least one of the other first line
drugs. Most significant is the inability of such assays to detect
15.5% cases with isoniazid resistance, of which 4% are isoniazid
mono-resistant. A recent retrospective analysis of aggregated data
from more than 81 countries, also showed isoniazid resistance of
14.5% in rifampicin susceptible isolates from high MDR (.4.58%)
prevalent cohorts of combined TB cases [10]. The isoniazid
resistance rates in our population are comparable to estimated
prevalence from WHO South-East Asian region of 15.7% in
combined cases [5]. Treatment of such isolates with first line ATT
risk clinical failure with a high probability of progression to MDR-
TB. Poor outcomes are reported in 16% and progression to MDR-
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TB in 61% cases of TB patients infected with isoniazid mono-
resistant strains that are treated with standard four drug therapy
(HRZE) [2]. A meta-analysis and review of isoniazid mono-
resistant cases showed that even use of three drugs in the
continuation phase (2HRZES/1HRZE/5HRE) was associated
with failure rates of 18–44% [3]. The same meta-analysis further
reports 3 studies with a combined treatment failure and relapse
rate of 29% to 70% in previously treated patients on standardized
TB treatment (2HRZ6E)/4HR [3]. These findings are supported
by a recent study from Georgia documenting 29% treatment
failure rate in isoniazid mono-resistant cases when compared to
individuals with isoniazid susceptible TB [4].
Pyrazinamide resistance was detected in 7.5% of rifampicin
susceptible cases in our population. Decreased odds of successful
clinical outcomes are also reported in pyrazinamide resistant as
compared with pan-susceptible TB [11].
Disturbingly, our findings suggest that when rifampicin suscep-
tibility alone is taken into account 2.7% of patients on HRZE and
1.7% on SHRZE in the intensive phase are likely to be receiving
rifampicin as the only effective agent. Another important finding is
the distribution of isoniazid mono-resistant strains throughout the
country. A finding that precludes identification of any particular
geographical area as being at higher risk for isoniazid mono-
resistant isolates. Our study is limited by its retrospective design
and lack of history of prior antimicrobial chemotherapy and
clinical outcomes. High resistance rates in this study could
therefore be a result of selection bias due to greater number of
complicated and treatment failure cases being referred for DST in
Table 1. Resistance to first line anti-tuberculosis agents* amongst rifampicin susceptible Mycobacterium tuberculosis isolates.
Years
2009 2010 2011 2009–2011
n (%){ n (%){ n (%){ n (%){
Number of isolates 1414 1432 1337 4183
Strain susceptibility/resistance
Susceptible to all 1st line* drugs 1026 (72.5) 1067 (74.5) 957 (71.5) 3050 (73)
Resistance to any of the 1st line* drugs 388 (27.5) 365 (25.5) 380 (28) 1133 (27)
Any Resistance#
H 191 (13.5) 245 (17) 213 (16) 649 (15.5)
Z 53 (3.7) 109 (7.6) 152 (11) 314 (7.5)
E 45 (3) 95 (6.6) 67 (5) 207 (5)
S 293 (19.6) 253 (17) 250 (19) 796 (19)
Mono resistance
H 61 (4.3) 71 (5) 42 (3) 174 (4)
Z 1 (0) 0 (0) 0 (0) 1 (0)
E 8 (0.5) 23 (1.6) 13 (1) 44 (1)
S 181 (10.4) 117 (8) 147 (11) 445 (10.6)
Combined resistance of H with other 1st line drugs
H+Z 11 (3.7) 29 (2) 60 (5) 100 (2.3)
H+E 7 (0.5) 4 (0.2) 2 (0.1) 13 (0.3)
H+S 70 (5) 50 (3.5) 17 (1.2) 137 (3.3)
H+Z+S 18 (1.2) 35 (2.4) 49 (3.7) 102 (2.4)
H+E+S 1 (0) 11 (0.7) 0 (0) 12 (1)
H+Z+E 6 (0.4) 17 (1.2) 17 (1.3) 40 (1)
H+Z+E+S 17 (1.2) 28 (2) 25 (2) 70 (1.7)
*Isoniazid (H); Pyrazinamide (Z); Ethambutol (E); Streptomycin (S).
#Any resistance, either singly or in combination with other 1st line drugs.
{%, Susceptible or resistant isolates expressed as a percentage of total rifampicin susceptible strains isolated during stated time period.
doi:10.1371/journal.pone.0050551.t001
Table 2. Province wise distribution of isoniazid mono-
resistance amongst rifampicin susceptible isolates: 2009–
2011.
Province 2009 2010 2011
R(s)
H(r)
n (%)* R(s)
H(r)
n (%)* R(s)
H(r)
n (%)*
Punjab 263 20(7.6) 425 25(6) 396 11(3.2)
Sindh 964 31(3.2) 791 37(5) 703 20(3)
KPK 152 9(6) 159 8(5) 177 8(4.5)
Balochistan 35 1(3) 57 1(2) 61 3(5)
Total 1414 61(4.3) 1432 71(5) 1337 42(3)
R(s), rifampicin susceptible strains.
H(r), Isoniazid mono-resistant strains amongst rifampicin susceptible strains of
the respective province.
*%, Isoniazid mono-resistance amongst rifampicin susceptible strains of the
respective province.
KPK, Khyber Pakhtunkhwa.
doi:10.1371/journal.pone.0050551.t002
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our laboratory. High streptomycin monoresistance rate noted in
our study is likely to reflect the need for strengthening DOTS
program. Our findings further points to a need for a national drug
resistance survey program to assess the prevalence of drug
resistance nationwide.
Retrospective nature of our study did not allow us to perform
molecular strain typing and documenting clonality of isoniazid
mono-resistant strains. However, another study from our group
reported 76.3% sensitivity and 100% specificity of isoniazid
resistance detection using MTBDRplus assay (Hain Lifescience,
GmbH, Nehren, Germany) compared to the agar proportion
method in smear-positive pulmonary tuberculosis samples. This
study provides an insight of the prevalent mutations responsible for
isoniazid resistance in our region. Among isoniazid resistant
isolates 55.9% were reported has having mutations at codons 315
of katG gene and 11.9% in inhA promoter at positions 215.
MTBDRplus assay was not able to detect any mutation in 14
isoniazid-resistant strains. The study concluded that additional
probes were needed to be included in the MTBDRplus assay to
improve the detection of isoniazid-resistant MTB strains in
Pakistan [12]. Another study performed on MDR-TB strains
collected from the same laboratory showed that 63% of isolates
had a mutation at codon 315 of katG and 1.6% at promoter region
of the inhA [13]. Still another study during the same time period
performed on XDR strains also shows 82% mutation at codon 315
and 2% at codon 328 of katG. Among other mutations 4% isolates
had a transition at the inhA position –15 promoter and 6% at ahpC
position –88. No mutation in katG, inhA and ahpC was detected for
remaining 6% of isolates [14]. Although these two studies [13],
[14) excluded rifampicin susceptible isolates; they offer informa-
tion on the prevalent mutations accountable for isoniazid
resistance in our population.
Moderately high rates of katG and inhA mutations suggest that it
will be safer to screen for these in addition to rifampicin resistance
rather than categorize cases by screening for rifampicin resistance
alone.
In summary, the data demonstrates that in a considerable
proportion of isolates, resistance would be underreported by using
rifampicin-based assays alone. To avoid poor outcome in these
patients, the roll out of techniques such as Xpert MTB/RIF, need
to be accompanied by strict monitoring of outcome including
sputum conversion for early detection of strains that are rifampicin
susceptible but resistant to one or more of the other first line
agents. We also recommend that DST or rapid diagnostic tests
detecting both isoniazid and rifampicin resistance should be
performed particularly in high risk MDR-TB population.
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